Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments (Q41082086)

26 September 2017

title

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments (English)

1 reference

26 September 2017

0 references

5

1 reference

26 September 2017

2

Eric Nuermberger

1 reference

26 September 2017

Jotam G Pasipanodya

1

1 reference

26 September 2017

Klaus Romero

series ordinal

3

1 reference

26 September 2017

Debra Hanna

series ordinal

4

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 August 2015

1 reference

Clinical Infectious Diseases

26 September 2017

published in

1 reference

26 September 2017

volume

61 Suppl 1

1 reference

26 September 2017

page(s)

S10-7

1 reference

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Nonclinical models for antituberculosis drug development: a landscape analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

21 January 2018

The Monte Carlo Method

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Biological variability and the emergence of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV425

21 January 2018

Identifiers

DOI

10.1093/CID/CIV425

1 reference

26 September 2017

1 reference